vasoactive-intestinal-peptide and Medulloblastoma

vasoactive-intestinal-peptide has been researched along with Medulloblastoma* in 1 studies

Other Studies

1 other study(ies) available for vasoactive-intestinal-peptide and Medulloblastoma

ArticleYear
Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood.
    International journal of cancer, 1999, Apr-12, Volume: 81, Issue:2

    Vasoactive intestinal peptide (VIP) is a neuromodulator and growth regulator in the developing nervous system. We analyzed 10 primitive neuroectodermal tumor (PNET) cell lines, 29 central PNET (cPNET) and 17 tumors of the Ewing's sarcoma/peripheral PNET family (ESFT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern hybridization. Each of the 10 cell lines and 86.2% of cPNET expressed mRNA for VIP receptor 1 (VIPR1) compared to 52.9% of ESFT. VIPR2 was expressed in 75.8% of cPNET, in 28.6% of ESFT and in all 10 cell lines. cPNET demonstrated high-affinity binding of 125I-VIP on quantitative autoradiography and in competitive binding assays. VIP inhibited tumor cell proliferation in a dose-dependent manner in 5 of 7 PNET cell lines. We conclude that VIPR1 and VIPR2 are highly expressed in cPNET and demonstrate that VIP is a growth modulator in these tumors.

    Topics: Autoradiography; Blotting, Southern; Cell Division; Child; Female; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Receptors, Vasoactive Intestinal Peptide; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Vasoactive Intestinal Peptide

1999